Tela Bio Inc (TELA)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$0.82+5.19%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · TELA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -80.0% |
| Our one-year growth estimate | diamond | 6.7% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 86.7 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
TELA — CFO transition
Dated 2026-08-31
CFO — Roberto Cuca: The CFO and COO is being terminated without cause, representing a significant loss of senior management.
Why it matters: Plans to extend cash runway are vital for the company's survival. They help the company carry out its plans.
Watch forManagement provides a clear plan to extend cash runway by at least 12 months.
Also watch forNo actionable plan is presented to extend the cash runway.
Why it matters: Faster sales of OviTex LTR show the product is accepted in the market.
Supportive ifOviTex LTR sales grow by at least 15% year over year.
Worry ifOviTex LTR sales decline or show no growth year over year.
Why it matters: Positive revenue growth shows recovery from recent drops. It helps management's growth goals.
Supportive ifQ3 revenue shows growth of at least 1% year over year.
Worry ifQ3 revenue declines further year over year.
Why it matters: A loss above this level shows financial problems. It may worry investors about making money.
Worry ifNet loss reported above $12 million in Q2 2026.
Less concerning ifNet loss reported below $12 million in Q2 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$453 on $10,000 · ±4.5% | How much price usually moves either way. |
| Bad day | $890 loss on $10,000 · 8.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,541 loss on $10,000 · 65.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Achieving this growth would signal recovery after the recent revenue decline. It is crucial for meeting management's growth target.
Supportive ifQ3 revenue growth exceeds 8% compared to Q3 2025.
Worry ifQ3 revenue growth is below 0% year over year.
Why it matters: Sustained high growth in Europe supports TELA's international expansion strategy. It shows demand for their products is strong.
Supportive ifEuropean revenue growth reported above 40% year over year.
Worry ifEuropean revenue growth reported below 30% year over year.
Why it matters: Management's cost-cutting plan is important. It helps keep cash longer and improves finances.
Supportive ifManagement says they saved at least $8 million each year from the cost-cutting plan.
Worry ifManagement says savings from the cost-cutting plan are under $5 million.
Why it matters: Better unit volumes are important. They can help stop recent drops in revenue and aid growth.
Supportive ifOviTex PRS unit volumes increase by more than 10% in Q3 2026 compared to Q2 2026.
Worry ifOviTex PRS unit volumes drop more in Q3 2026 than in Q2 2026.
Why it matters: Continued growth abroad can help with problems at home and boost total revenue.
Supportive ifInternational revenue growth exceeds 25% year over year in Q3 2026.
Worry ifInternational revenue growth falls below 15% year over year in Q3 2026.